Abstracts tagged "autoimmune diseases"

Abstract Number: 0949 • ACR Convergence 2025
The Cancer-associated Female-biased Factor VGLL3 Drives Autoimmunity and Fibrosis
Mehrnaz Gharaee-Kermani¹, Poulami Dey², Vincent van Drongelen¹, Joanna Rew¹, Rachael Bogle³, Marisa Hildebrandt¹, Benjamin Klein¹, Rezvan Moallemian¹, Monique E Verhaegen¹, Andrzej A Dlugosz⁴, Lam Tsoi¹, J. Michelle Kahlenberg¹, Johann Gudjonsson¹ and Allison C Billi¹, ¹University of Michigan, Ann Arbor, MI, ²Michigan Medicine, Ann Arbor, MI, ³University of Michigan, Holland, OH, ⁴University of Michigan, Ann Arbor
Background/Purpose: Autoimmune disease is far more common in women than men. We have determined that the skin of healthy women is primed for autoimmunity due…
Abstract Number: 0906 • ACR Convergence 2025
Preclinical Characterization of IBI3034, an TACI and BCMA Chimeric Fc Fusion Protein, that Potently Modulates B Lymphocytes and Serum Immunoglobulin for the Treatment of B cell Related Autoimmune Disease
Yao Xiong, Shuaixiang Zhou, Zhimin Zhang, Bin Li, Zhihao Ming, Yuyu Wu, Liu Li, Chang Li, Fenggen Fu, Zhihai Wu, Shun Wang, Guogang Yuan, Yuling Song, Jinyang Li, Huizhong Xiong and Bingliang Chen, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: Dysregulated B-cell activation plays a pivotal role in the pathogenesis of various autoimmune diseases. B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are…
Abstract Number: 0608 • ACR Convergence 2025
Strong Correlation Between SLEDAI and SLE-DAS in the Spanish Population: Assessment of Discordant Patients
Elena Heras Recuero¹, Antia Garcia Fernandez², Cristina Gomez-Moreno³, Ivan Ferraz Amaro⁴, Javier Llorca⁵ and Miguel A. González-Gay⁶, ¹Hospital Fundacion Jimenez Dias, Madrid, Spain, ²Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ³Fundacion Jiménez Díaz School of Nursing, Madrid, Autonomous University Madrid, Madrid, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵CIBER Epidemiología y Salud Pública (CIBERESP) and Department of Medical and Surgical Sciences, University of Cantabria, Santander, Spain, ⁶Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain
Background/Purpose: Assessing disease activity in systemic lupus erythematosus (SLE) is essential for effective treatment. SLEDAI-2K uses dichotomous items, while SLE-DAS incorporates both dichotomous and continuous…
Abstract Number: 0792 • ACR Convergence 2025
Real-World Assessment of Glucocorticoid-Induced Skin Toxicity in Individuals with Rheumatic Diseases
Tania Chiha¹, Jiaqi Wang², Isha Jha³, Grace McMahon³, John Stone⁴ and Naomi Patel³, ¹Mount Auburn Hospital, Boston, MA, ²Massachusetts General Hospital, BOston, ³Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital , Harvard Medical School, Concord, MA

Background/Purpose: Glucocorticoids (GC) are used to treat various inflammatory and autoimmune diseases, though despite widespread use, real-world data on skin-specific GC toxicity are limited. To…
Abstract Number: 0356 • ACR Convergence 2025
An Analysis of Osteoporosis Screening in Males 50 and Older with Rheumatic Disease across Stony Brook Medicine Network
Stephen Poos¹, Hoang Nguyen², Samuel Greenberg³, Marcus Lee², Heidi Roppelt¹ and Asha Patnaik², ¹Stony Brook Southampton Hospital, Southampton, NY, ²Stony Brook University Hospital, Stony Brook, NY, ³Renaissance School of Medicine at Stony Brook University, Stony Brook, NY
Background/Purpose: Osteoporosis is under screened in men. The United States Preventive Services Task Force (USPSTF) does not publish guidelines for osteoporosis screening in men. Other…
Abstract Number: 0263 • ACR Convergence 2025
A Multicenter Retrospective Case Series of Patients with Susac Syndrome treated with Rituximab
Michelle Benjamin¹, Mattia Wruble Clark², Shamik Bhattacharyya³, Audra Horomanski¹ and Kristin Galetta⁴, ¹Stanford University, Palo Alto, CA, ²Mass General Brigham, Somerville, MA, ³Brigham and Women's Hospital, Malden, MA, ⁴Stanford Medical Center, Palo Alto
Background/Purpose: Susac Syndrome (SuS) is a rare immune-mediated vasculo-occlusive disease characterized by a triad of encephalopathy, hearing loss, and branched retinal artery occlusions. Deficits can…
Abstract Number: 0201 • ACR Convergence 2025
Real-World study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus Kinase Inhibitors in comparison with healthy individuals
Ana Victoria Esteban Vázquez¹, Martina Steiner², Cristina Vergara², Elisabet Castañeda Estévez³, Maria Beatriz Paredes Romero⁴, Isabel De La Camara-Fernandez¹, Laura Trives¹, Tatiana Cobo¹, Patricia Richi⁵, Maria liz Romero⁵, Marta De San Segundo³, Antonio Sanchis³, Carolina Marín⁶, Maria Teresa Navio Marco⁷ and Santiago Muñoz¹, ¹Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ²Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Madrid, Spain, ³Hospital Universitario Infanta Sofía, Madrid, Spain, ⁴Infanta Sofía University Hospital, Madrid, Spain, ⁵Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de Los Reyes, Madrid, Spain, ⁶Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ⁷Infanta Leonor Universitary Hospital, Madrid, Spain
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) receiving Janus Kinase Inhibitors (JAKi) are at increased risk of herpes zoster reactivation. The adjuvanted recombinant zoster vaccine…
Abstract Number: 0062 • ACR Convergence 2025
Neddylation as a Therapeutic Target in Autoimmune Arthritis: Evidence from SKG Mice
Sho Sendo¹, Alfonso Del Peral Fanjul², Kazuma Nishisaka², Hirotaka Yamada¹, Takaichi Okano¹, Keisuke Nishimura¹, Yo Ueda¹ and Jun Saegusa², ¹Kobe University Hospital, Kobe, Japan, ²Kobe University, Kobe, Japan
Background/Purpose: Neddylation, NEDD8 conjugating process, is a post-translational modification that plays a crucial role in regulating ubiquitination by targeting cullin (CUL)-ring E3 ubiquitin ligases. Our…
Abstract Number: 0009 • ACR Convergence 2025
MRT-6160, a VAV1-Directed Molecular Glue Degrader, Attenuates T and B Cell Effector Functions and Inhibits Disease Progression in a Spontaneous MRL-Faslpr Mouse Model
Adam Cartwright¹, Lucas Gyger¹, Foram Desai², Shailee Vora², Anna Kostikova¹, Xudong Wang², Peter Trenh², Katie May², Sophia Nguyen², Chris King², Daniel Lam², Xavi Lucas¹, Mary Zlotosch², Elisa Liardo¹, Daric Wible², Ilaria Lamberto², Bradley Demarco², Debora Bonenfant¹, Sharon Townson², Eswar Krishnan², Filip Janku², John Castle¹, Laura McAllister¹, Alison Paterson² and Marisa Peluso², ¹Monte Rosa Therapeutics, Basel, Switzerland, ²Monte Rosa Therapeutics, Boston, MA
Background/Purpose: VAV1, an immune cell restricted guanine nucleotide exchange factor (GEF) and scaffolding protein, plays a critical role in mediating T- and B-cell receptor activity.…
Abstract Number: 2684 • ACR Convergence 2025
Multimodal Analysis Revealed Altered Brain Connectivity Patterns and Neuroinflammatory Processes in the Background of Difficult-To-Treat Rheumatoid Arthritis
Lilla Gunkl-Tóth¹, Gergely Orsi², Noémi Császár-Nagy³, Lili Duzsik⁴, Gábor Mátay⁴, Gábor Kumánovics⁵, Gábor Sütő², Krisztina Csókási², Szabolcs Takács⁶, Zoltán Vidnyánszky⁷, József Kun², Krisztina Takács-Lovász², Gellért Karvaly⁸, Róbert Farkas⁸, Anett Pintér⁸, Panna Királyhidi⁸, György Nagy⁸ and Zsuzsanna Helyes², ¹Semmelweis University, Budapest, Budapest, Hungary, ²University of Pécs, Pécs, Hungary, ³National University of Public Services, Budapests, Hungary, ⁴Psychosomatic Outpatient Clinic, Budapest, Hungary, ⁵University of Pecs, Pecs, Hungary, ⁶Károli Gáspár University, Budapest, Hungary, ⁷Brain Imaging Centre, Research Centre for Natural Sciences, Budapest, Hungary, ⁸Semmelweis University, Budapest, Hungary
Background/Purpose: Despite advances in rheumatoid arthritis (RA) treatment, 5–20% of patients experience persistent symptoms, particularly pain, and are classified as difficult-to-treat (D2T). Factors such as…
Abstract Number: 2578 • ACR Convergence 2025
Association of Oral Outpatient Antiviral Medications for COVID-19 with the Risk of Post-Acute Sequelae of COVID-19 in Individuals with Systemic Autoimmune Rheumatic Diseases
Madison Negron¹, Jiaqi Wang², Xiaosong Wang³, Lauren O'Keeffe⁴, Grace Qian⁴, Kevin Mueller⁴, Alene Saavedra⁴, Natalie Davis⁵, Liya Sisay Getachew⁶, Jeffrey Sparks⁶ and Naomi Patel⁷, ¹Harvard Extension School, Medford, MA, ²Massachusetts General Hospital, BOston, ³Brigham and Women's Hospital, Natick, MA, ⁴Brigham and Women's Hospital, Boston, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Massachusetts General Hospital, Boston, MA
Background/Purpose: Prior studies have evaluated the efficacy of antiviral medications on acute outcomes of COVID-19 infection as well as the risk of post-acute sequelae of…
Abstract Number: 1258 • ACR Convergence 2025
Upadacitinib in the treatment of Rheumatoid Arthritis – Interstitial Lung Disease. National multicenter study of 25 patients in clinical practice.
Ana Serrano-Combarro¹, Belén Atienza-mateo², Leticia del Olmo Perez³, Sara García-Perez⁴, Guillermo Gonzalez Mozo de Rosales⁵, Jose Rosas Gómez de Salazar⁶, ana Urruticoechea-Arana⁷, Andrea García-Valle⁸, Jesús Loarce⁹, Paula García-Escudero¹⁰, Bryan Josué Flores Robles¹¹, Rafael B. Melero-González¹², Alicia Garcia¹³, Maria Martín López¹⁴, Patricia López Viejo¹⁵, Maria Jose Perez Gaan¹⁶, Nuria Vegas Revenga¹⁷, Angel Garcia-Aparicio¹⁸, M.Pilar Bernabeu Gonzalvez¹⁹, Juan Moreno Morales²⁰ and Ricardo Blanco²¹, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, ³HGU Nuestra Señora del Prado, Talavera de la Reina, Talavera de la Reina, Spain, ⁴Complejo Hospitalario de Vigo, Vigo, Spain, ⁵Basurto University Hospital, Bilbao, Spain, ⁶Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ⁷Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, ⁸Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, ⁹Ramón y Cajal University Hospital, Madrid, Spain, ¹⁰Hospital Universitario Álava, Bilbao, Spain, ¹¹Hospital San Pedro, Logroño, Spain, ¹²COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ¹³Rheumatologist, La Laguna, Spain, ¹⁴Hospital ¹² de Octubre, Madrid, Spain, ¹⁵Hospital Severo Ochoa (Leganés), Leganes, Spain, ¹⁶Hospital Universitario Virgen de las Nieves, Granada, Spain, ¹⁷Galdakao- Usansolo University Hospital, Galdakao, Spain, ¹⁸Hospital Universitario de Toledo, Toledo, Spain, ¹⁹Rheumatology Department, Dr. Balmis General University Hospital, Alicante, Spain., Alicante, Spain, ²⁰Hospital Universitario Santa Lucia Cartagena, Cartagena, Spain, ²¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and rituximab are usually the recommended drugs. JAK inhibitors (JAKi)…
Abstract Number: 2267 • ACR Convergence 2025
Impact of Baseline Cardiovascular Risk Factors Comorbidities on an Adalimumab Biosimilar Efficacy, Quality of Life and Safety In Patients with Patients with Moderately to Severely Active Rheumatoid Arthritis: Results from the AURIEL-RA study
Chris Edwards¹, Janet Pope², Joelle Monnet³ and Maria Romanova Michailidi⁴, ¹University Hospital Southampton, Southampton, United Kingdom, ²University of Western Ontario, London, ON, Canada, ³Fresenius Kabi SwissBioSim, Eysins, Switzerland, ⁴University of Geneva, Eysins, Switzerland
Background/Purpose: RA has been associated with an increase risk of cardiovascular morbidity and mortality1. The present analysis was performed to assess the efficacy (on ACR…
Abstract Number: 1944 • ACR Convergence 2025
Musculoskeletal Ultrasound Clinic Referral Patterns and Joint Findings in a Tertiary Care Center amongst Patients with Elevated BMI and Inflammatory Arthritis
Anna Lichtiger¹, Ying Jin², Caroline Rourke¹, Kiera Brennan³, Hillary Weisleder⁴, Melissa Fazzari⁵ and Melissa Band⁶, ¹Montefiore Medical Center, The Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ⁴Montefiore Einstein, New York, NY, ⁵Department of Epidemiology & Population Health, Albert Einstein College of Medicine,, Bronx, NY, ⁶Montefiore Medical Center, New York, NY
Background/Purpose: Musculoskeletal ultrasound (MSUS) has been well known to aid in both early diagnosis and monitoring of inflammatory arthritis. Patients with an elevated BMI have…
Abstract Number: 1772 • ACR Convergence 2025
Correlation between Soluble Checkpoint Molecules and Disease Activity in Autoimmune Diseases
Kosaku Murakami¹, Akiko Yoshida², Hitoshi Uga³, Shuji Sumitomo⁴, Koichiro Ohmura⁵, Ryosuke Hiwa⁶, Tomohiro Kozuki⁷, Mao Kuroishi³, Chihiro Suminaka³, Mirei Shirakashi⁶, Hideaki Tsuji⁸, Shuji Akizuki⁶, Ran Nakashima⁶, Hajime Yoshifuji⁶, Akira Onishi⁹, Masao Tanaka⁹, Akio Morinobu¹⁰, Kenji Chamoto⁷ and Tasuku Honjo⁷, ¹Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ²Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Central Research Laboratories, Sysmex corporation, Kobe, Hyogo, Japan, ⁴Kobe City Medical Center General Hospital, Kobe city, Hyogo, Japan, ⁵Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan, ⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ⁷Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ⁸Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁹Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ¹⁰Kyoto University, Kyoto, Kyoto, Japan
Background/Purpose: Soluble checkpoint molecules (sCM) may be involved in the pathophysiology of autoimmune diseases by inhibiting the suppressive signals of immune cell activation through binding…

« Previous Page
1
…
4
5
6
7
8
…
101
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].